 Epigenetic silencing of DCC by promoter hypermethylation has shown to be a significant factor in other cancer types.In head and neck squamous cell carcinoma, 77.3% of tumour samples presented DCC promoter hypermethylation versus 0.8% in non-cancerous saliva samples.Similar results have been seen in breast cancer, acute lymphoblastic leukemia, and several others.